Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 429-440 , July 2010

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression

References 

  1. Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell. 2004;6:111–116
  2. Olumi AF, Tsai YC, Nichols PW, et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 1990;50:7081–7083
  3. Tsai YC, Nichols PW, Hiti AL, et al. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res. 1990;50:44–47
  4. Ruppert JM, Tokino K, Sidransky D. Evidence for 2 bladder cancer suppressor loci on human chromosome 9. Cancer Res. 1993;53:5093–5095
  5. Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome 9 in human bladder cancer. Cancer Res. 1993;53:4066–4070
  6. Cairns P, Shaw ME, Knowles MA. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res. 1993;53:1230–1232
  7. Keen AJ, Knowles MA. Definition of 2 regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene. 1994;9:2083–2088
  8. Simoneau AR, Spruck CH, Gonzalez-Zulueta M, et al. Evidence for 2 tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res. 1996;56:5039–5043
  9. Cairns JP, Chiang PW, Ramamoorthy S, et al. A comparison between microsatellite and quantitative PCR analyses to detect frequent p16 copy number changes in primary bladder tumors. Clin Cancer Res. 1998;4:441–444
  10. Salem C, Liang G, Tsai YC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res. 2000;60:2473–2476
  11. Williamson MP, Elder PA, Shaw ME, et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet. 1995;4:1569–1577
  12. Cairns P, Tokino K, Eby Y, et al. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res. 1994;54:1422–1424
  13. Papageorgiou A, Dinney CP, McConkey DJ. Interferon-α induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007;6:872–879
  14. Papageorgiou A, Lashinger L, Millikan R, et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. 2004;64:8973–8979
  15. Hornigold N, Devlin J, Davies AM, et al. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene. 1999;18:2657–2661
  16. Knowles MA, Habuchi T, Kennedy W, et al. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res. 2003;63:7652–7656
  17. Knowles MA, Hornigold N, Pitt E. Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem Soc Trans. 2003;31:597–602
  18. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22
  19. Chow NH, Cairns P, Eisenberger CF, et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer. 2000;89:514–518
  20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  21. Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes (A study of the urothelium in 10 surgically removed bladders). JAMA. 1974;227:281–286
  22. Majewski T, Lee S, Jeong J, et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008;88:694–721
  23. Lee S, Jeong J, Majewski T, et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci USA. 2007;104:13732–13737
  24. Crawford JM. The origins of bladder cancer. Lab Invest. 2008;88:686–693
  25. Deng J, Carlson N, Takeyama K, et al. BH3 profiling identifies 3 distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12:171–185
  26. Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2:183–192
  27. Fleischer A, Rebollo A. Induction of p53-independent apoptosis by the BH3-only protein ITM2Bs. FEBS Lett. 2004;557:283–287
  28. Fleischer A, Ayllon V, Dumoutier L, et al. Proapoptotic activity of ITM2B(s), a BH3-only protein induced upon IL-2-deprivation which interacts with Bcl-2. Oncogene. 2002;21:3181–3189
  29. Azeem Z, Jelani M, Naz G, et al. Novel mutations in G protein-coupled receptor gene (P2RY5) in families with autosomal recessive hypotrichosis (LAH3). Hum Genet. 2008;123:515–519
  30. Shimomura Y, Wajid M, Ishii Y, et al. Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat Genet. 2008;40:335–339
  31. Pasternack SM, von Kugelgen I, Aboud KA, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008;40:329–334
  32. Song H, Ramus SJ, Shadforth D, et al. Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Res. 2006;66:10220–10226
  33. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001;20:1973–1980
  34. Mo L, Zheng X, Huang HY, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest. 2007;117:314–325
  35. Zhang ZT, Pak J, Shapiro E, et al. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999;59:3512–3517
  36. Cheng J, Huang H, Pak J, et al. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res. 2003;63:179–185
  37. Gao J, Huang HY, Pak J, et al. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene. 2004;23:687–696
  38. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and PTEN promotes invasive bladder cancer. Genes Dev. 2009;23:675–680
  39. Yoo LI, Liu DW, Le Vu S, et al. PTEN deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res. 2006;66:1929–1939
  40. Czerniak B, Cohen GL, Etkind P, et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992;23:1199–1204
  41. Knowles MA, Williamson M. Mutation of H-Ras is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res. 1993;53:133–139
  42. Karimianpour N, Mousavi-Shafaei P, Ziaee AA, et al. Mutations of RAS gene family in specimens of bladder cancer. Urol J. 2008;5:237–242
  43. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001;20:686–691
  44. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene. 2001;20:4416–4418
  45. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: Biomarker and potential therapeutic target. World J Urol. 2007;25:581–593
  46. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 2007;26:5889–5899
  47. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest. 2009;119:1216–1229
  48. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–1264
  49. Esrig D, Spruck CH, Nichols PW, et al. p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993;143:1389–1397
  50. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRB expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22:1007–1013
  51. Shariat SF, Bolenz C, Karakiewicz PI, et al. p53 Expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105:409–415
  52. Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 Predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009;182:907–913
  53. George B, Datar RH, Wu L, et al. p53 Gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 2007;25:5352–5358
  54. Xu HJ, Cairns P, Hu SX, et al. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer. 1993;53:781–784
  55. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRB expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998;58:1090–1094
  56. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumor-suppressor gene on chromosome 9. Oncogene. 1993;8:1083–1085
  57. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998;16:3215–3218
  58. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997;57:5221–5225
  59. Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer. 1999;80:904–908
  60. Wang DS, Rieger-Christ K, Latini JM, et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer. 2000;88:620–625
  61. Harris LD, De La Cerda J, Tuziak T, et al. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog. 2008;47:678–685
  62. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007;104:7564–7569
  63. Gildea JJ, Herlevsen M, Harding MA, et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene. 2004;23:6788–6797
  64. Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15:6008–6017
  65. Askham JM, Platt F, Chambers PA, et al. AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that can cooperate with E17K. Oncogene. 2010;29:150–155
  66. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11:4044–4055
  67. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778–789
  68. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–527
  69. Peinado H, Olmeda D, Cano A. Snail, Zeb, and bHLH factors in tumor progression: An alliance against the epithelial phenotype?. Nat Rev Cancer. 2007;7:415–428
  70. Onder TT, Gupta PB, Mani SA, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68:3645–3654
  71. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathologic stage of renal cell carcinoma. Am J Pathol. 2001;158:735–743
  72. Anzai H, Kitadai Y, Bucana CD, et al. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer. 1998;34:558–565
  73. Kitadai Y, Ellis LM, Takahashi Y, et al. Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. Clin Cancer Res. 1995;1:1095–1102
  74. Greene GF, Kitadai Y, Pettaway CA, et al. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol. 1997;150:1571–1582
  75. Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 2006;66:4549–4552
  76. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927–939
  77. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715
  78. Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004;171:570–574
  79. Inoue K, Kamada M, Slaton JW, et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res. 2002;8:1863–1870
  80. Dinney CP, Fishbeck R, Singh RK, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol. 1995;154:1532–1538
  81. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999;5:257–265
  82. Shrader M, Pino MS, Brown G, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007;6:277–285
  83. Black PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008;14:1478–1486
  84. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65:9455–9462
  85. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006;66:944–950
  86. Yauch RL, Januario T, Eberhard DA, et al. Epithelial vs. mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005;11:8686–8698
  87. Haddad Y, Choi W, McConkey DJ. δ-Crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res. 2009;15:532–542
  88. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009;15:5060–5072
  89. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22:894–907
  90. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601
  91. Hurteau GJ, Carlson JA, Spivack SD, et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007;67:7972–7976
  92. Di Como CJ, Urist MJ, Babayan I, et al. p63 Expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494–501
  93. Urist MJ, Di Como CJ, Lu ML, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002;161:1199–1206
  94. Koga F, Kawakami S, Fujii Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003;9:5501–5507
  95. Koga F, Kawakami S, Kumagai J, et al. Impaired Delta Np63 expression associates with reduced β-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer. 2003;88:740–747
  96. Signoretti S, Pires MM, Lindauer M, et al. p63 Regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005;102:11355–11360
  97. Senoo M, Pinto F, Crum CP, et al. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. F. Cell. 2007;129:523–536
  98. Yi R, Poy MN, Stoffel M, et al. A skin microRNA promotes differentiation by repressing ‘stemness'. Nature. 2008;452:225–229
  99. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111
  100. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature. 1994;367:645–648
  101. He S, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol. 2009;25:377–406
  102. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009;23:2563–2577
  103. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008;26:2813–2820
  104. Kurzrock EA, Lieu DK, Degraffenried LA, et al. Label-retaining cells of the bladder: Candidate urothelial stem cells. Am J Physiol Renal Physiol. 2008;294:F1415–F1421
  105. He X, Marchionni L, Hansel DE, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells. 2009;27:1487–1495
  106. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009;106:14016–14021
  107. Brandt WD, Matsui W, Rosenberg JE, et al. Urothelial carcinoma: Stem cells on the edge. Cancer Metastasis Rev. 2009;28:291–304
  108. Farsund T. Cell kinetics of mouse urinary bladder epithelium (II. Changes in proliferation and nuclear DNA content during necrosis regeneration, and hyperplasia caused by a single dose of cyclophosphamide). Virchows Arch B Cell Pathol. 1976;21:279–298
  109. Mills AA, Zheng B, Wang XJ, et al. p63 Is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708–713
  110. Koster MI, Kim S, Mills AA, et al. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004;18:126–131
  111. McKeon F. p63 and the epithelial stem cell: More than status quo?. Genes Dev. 2004;18:465–469
  112. Cheng W, Jacobs WB, Zhang JJ, et al. δNp63 plays an anti-apoptotic role in ventral bladder development. Development. 2006;133:4783–4792

PII: S1078-1439(10)00118-3

doi: 10.1016/j.urolonc.2010.04.008

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 429-440 , July 2010

Article Tools

* Image Usage & Resolution